ArticleBMJ open2026

Availability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study.

Zhuangqi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.